Cartalax Reconstitution Calculator

No. Cartalax is a Russian peptide bioregulator from the Khavinson/St. Petersburg Institute line, marketed as a dietary supplement (food additive), not an approved drug in the US or EU. No human RCTs on Cartalax exist in the published literature; the highest available evidence is human-cell in vitro work. The published literature contains no regulatory or controlled human safety data for this compound (informational).

Cartalax is the commercial cartilage-tropic bioregulator built on the tripeptide AED (Ala-Glu-Asp) (community protocol/practitioner consensus). The published literature does not use the name "Cartalax," but the AED peptide and the related cartilage polypeptide complex (CPC) are the compounds consistently studied for chondrocyte and cartilage regeneration.

Three mechanisms are documented in human-cell models (in vitro): (1) AED at 200 ng/ml activates the chondrogenic differentiation program (SOX9, aggrecan, type II collagen, and COMP) in aging human mesenchymal stem cells (MSCs); (2) AED normalizes the senescence-associated secretory phenotype (SASP) of aging chondrocytes, reducing pro-apoptotic/pro-inflammatory markers (p16, p21, p53, TNF-α, IL-1α) and restoring Sirt1; (3) in skin fibroblasts, AED upregulates sirtuin-1, sirtuin-6, and collagen I synthesis. AED also modulates IGF1 and NF-κB expression in aging MSC cultures. Sirtuin activation plus SASP suppression is the proposed geroprotective basis for cartilage support (mechanistic).

Both forms exist; Cartalax is produced as oral capsules and an injectable solution. The in vitro benchmark is AED 200 ng/ml for maximal chondrogenic gene activation, which confirms potency at low concentrations but cannot be directly converted to a human dose (in vitro). Community protocol: oral, 1 capsule (10 mg) 1–2× daily for 30 days; injectable, 1–2 ml intramuscular daily or every other day for 20–30 days. Injectable delivery bypasses gastrointestinal breakdown of the short peptide, but capsules dominate real-world use for convenience (community protocol).

Standard practice is cyclic, not continuous: 30-day courses repeated 2–3 times per year (community protocol). The aging models showing benefit used replicative-aged chondrocytes and MSCs, consistent with periodic re-application rather than indefinite daily use (mechanistic). Long-term continuous human safety data are absent.

Different sequences, different targets. Cartalax's AED targets cartilage: chondrogenesis and chondrocyte SASP. Epitalon (Ala-Glu-Asp-Gly) is the pineal/neuroendocrine bioregulator with geroprotective, antioxidant, and melatonin-modulating actions. Both activate sirtuins (AED upregulates SIRT1/SIRT6 ); both derive from the same Khavinson bioregulator family. For joint and cartilage indications, AED/Cartalax is the targeted agent; Epitalon is a broader systemic geroprotector (practitioner consensus).

No pregnancy, lactation, or pediatric data exist in the published literature. Because AED drives differentiation programs (SOX9, collagen II) and modifies inflammatory cytokine balance, use during pregnancy or in children is not supported and should be avoided (practitioner consensus). General tolerability rests on benign in vitro outcomes and community experience; no controlled human safety trials exist in the published literature.

Capsules: no, store at room temperature, dry and dark (community protocol). Injectable ampoules/solutions: refrigerate after opening or reconstitution and use within the stated shelf-life (community protocol). Short peptide complexes are stable as lyophilized or encapsulated solids; degradation risk applies mainly to reconstituted liquids (mechanistic).